Trial Profile
Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Astrocytoma; Glioma; Neurofibromatosis 1
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2021 protocol was amended and approved by all regulatory groups (PBTC Scientific Committee,the PBTC DSMB and CTEP) to expand accrual to 25 patients in an effort to provide patients with a potentially beneficial treatment and evaluate further responses, toxicities, and survival in a descriptive fashion
- 01 Oct 2021 Results (n=25) of stratum 4 ,patients with sporadic (not associated with NF1) recurrent and progressive OPHGs published in the Neuro-Oncology
- 02 Apr 2021 Planned primary completion date changed from 31 Dec 2022 to 1 Dec 2025.